Sutent (sunitinib) is a small molecule pharmaceutical. Sunitinib was first approved as Sutent on 2006-01-26. It is used to treat gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, and renal cell carcinoma in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors, neuroendocrine tumors, and renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3, platelet-derived growth factor receptor beta, and mast/stem cell growth factor receptor Kit. In addition, it is known to target fibroblast growth factor receptor 1, receptor-type tyrosine-protein kinase FLT3, vascular endothelial growth factor receptor 2, proto-oncogene tyrosine-protein kinase receptor Ret, and platelet-derived growth factor receptor alpha. Sutent's patent is valid until 2021-02-15 (FDA).
|Indication||gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, renal cell carcinoma|
|Drug Class||Tyrosine kinase inhibitors|